AzurRx BioPharma, Inc. (NASDAQ:AZRX) was founded in 2014 and is headquartered in Brooklyn, New York, USA, with 13 full-time employees. It is a company that researches and develops non-systemic biological agents for the treatment of gastrointestinal diseases.
AzurRx BioPharma, Inc. (AZRX):
The AzurRx BioPharma product line includes two therapeutic proteins under development, including:
MS1819, a yeast-derived recombinant lipase, is in phase II clinical trials for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis.
AZX1101, a bacterial-derived enzyme combination, is used to prevent hospital-acquired infections and antibiotic-related diarrhea.